Lyell reports LYL314 Phase 1/2 data: 88% ORR, 72% CR in 3L+ LBCL

Lyell Immunopharma, Inc.

In efficacy-evaluable 3L+ patients (N=25), ORR 88% (22/25) with 72% CR; median follow-up 9 months.
71% (10/14) of CR patients remained in CR at ≥6 months; no Grade ≥3 CRS; no deaths related to LYL314.
In 2L patients (N=11), ORR 91% with 64% CR; 100% of CR patients in CR at last assessment (3/3 at ≥6 months).
Plan to initiate randomized pivotal trial of LYL314 in 2L R/R LBCL by early 2026.
LyFE manufacturing center expected to support >1,200 CAR T doses annually for clinical and early commercial use.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.